Location: Home > Pharma China Web Edition
  • search
  • go
  • Product/R&D News
  • 3/10/2026Junshi Secures NMPA Acceptance for Subcutaneous Toripalimab Across 12 ...
  • 3/9/2026Biocytogen Achieves Key Clinical Milestone as IDEAYA Initiates Phase I...
  • 3/9/2026Regeneron Highlights Positive Chinese Phase III Data for Obesity Candi...
  • 3/9/2026Kelun Biotech and Harbour BioMed's SKB575 Receives IND Clearance in Ch...
  • 3/9/2026Hansoh's B7-H3 ADC Shows Promising Lung Cancer Activity in Cancer Cell...
  • 3/9/2026Hansoh Reports Positive Phase 3 Results for Weekly GLP-1/GIP Dual Agon...
  • 3/9/2026Merck KGaA Drops Hengrui-Licensed PARP1 Candidate After Early Clinical...
  • 3/9/2026Abbisko's Pimicotinib Phase 3 MANEUVER Results Published in The Lancet
  • 3/6/2026China Approves Novo's Weekly Insulin–GLP-1 Combination Therapy for Ty...
  • 3/6/2026Abbisko Doses First Patient in Trial of KRAS G12D Inhibitor ABSK141
  • 3/6/2026Lynk's Zemprocitinib Meets Phase III Endpoints in Atopic Dermatitis
  • 3/6/2026Sciwind's Ecnoglutide Approved in China for Obesity
  • 3/5/2026CMS Wins China Trial Approval for INHBE-Targeting Obesity siRNA Drug
  • 3/4/2026CSPC's Emicizumab Injection Receives Clinical Trial Approval in China
  • 3/4/2026Minwei Biotech's siRNA Therapy MWX401 Cleared for Clinical Trials in C...
  • 3/4/2026Eli Lilly Advances New Oral Diabetes Therapy in China
  • 3/3/2026LongBio Pharma's LP‑003 Shows Superior Efficacy Over Xolair in Phase ...
  • 3/3/2026China Approves Five NMEs in February as Innovation Expands Globally
  • 3/2/2026China Approves Jaypirca for Expanded Blood Cancer Indications
  • 3/2/2026RemeGen NDA for RC288 Dual-Target ADC Accepted by NMPA
  • 3/2/2026MediLink Advances HER3 ADC YL202 Into Two Phase III Trials in China
  • 3/2/2026NMPA Approves Rovalicitinib for First-Line Myelofibrosis
  • 3/2/2026Innovent Registers Phase I Study for FIC Dual-Payload Bispecific ADC
  • 3/2/2026Sanofi Secures Two New China Approvals for Dupilumab
  • 2/27/2026CSPC Launches Phase III Program for SYH2053 PCSK9 siRNA in China
  • 2/27/2026Evopoint Biosciences Highlights Igermetostat Data at ASCO GU 2026 in m...
  • 2/26/2026BMS-Partnered Bispecific ADC Achieves Dual Survival Milestones in Chin...
  • 2/26/2026Health Guard's Trial Suspensions Deepen Pressure on China's HPV Vaccin...
  • 2/26/2026Jiuyuan Files for Approval of Wegovy Biosimilar in China
  • 2/26/2026Pfizer Updates Pneumococcal Vaccine Trial in China, Implications for I...
  • Page:1/22 Total number of articles:656: [First][<<] [1] [2] [3] [4] [5] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group